Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Immunoproteasome functions explained by divergence in cleavage specificity and regulation.

Winter MB, La Greca F, Arastu-Kapur S, Caiazza F, Cimermancic P, Buchholz TJ, Anderl JL, Ravalin M, Bohn MF, Sali A, O'Donoghue AJ, Craik CS.

Elife. 2017 Nov 28;6. pii: e27364. doi: 10.7554/eLife.27364.

2.

Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.

Johnson HWB, Anderl JL, Bradley EK, Bui J, Jones J, Arastu-Kapur S, Kelly LM, Lowe E, Moebius DC, Muchamuel T, Kirk C, Wang Z, McMinn D.

ACS Med Chem Lett. 2017 Mar 9;8(4):413-417. doi: 10.1021/acsmedchemlett.6b00496. eCollection 2017 Apr 13.

3.

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG.

Blood. 2016 Jun 30;127(26):3360-8. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12.

4.

Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying.

Lovalenti PM, Anderl J, Yee L, Nguyen V, Ghavami B, Ohtake S, Saxena A, Voss T, Truong-Le V.

Pharm Res. 2016 May;33(5):1144-60. doi: 10.1007/s11095-016-1860-1. Epub 2016 Jan 27.

PMID:
26818839
5.

Evaluation of Gallium Citrate Formulations against a Multidrug-Resistant Strain of Klebsiella pneumoniae in a Murine Wound Model of Infection.

Thompson MG, Truong-Le V, Alamneh YA, Black CC, Anderl J, Honnold CL, Pavlicek RL, Abu-Taleb R, Wise MC, Hall ER, Wagar EJ, Patzer E, Zurawski DV.

Antimicrob Agents Chemother. 2015 Oct;59(10):6484-93. doi: 10.1128/AAC.00882-15. Epub 2015 Aug 3.

6.

TP53 loss creates therapeutic vulnerability in colorectal cancer.

Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X.

Nature. 2015 Apr 30;520(7549):697-701. doi: 10.1038/nature14418. Epub 2015 Apr 22.

7.

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.

Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL.

J Exp Clin Cancer Res. 2014 Dec 31;33:111. doi: 10.1186/s13046-014-0111-8.

8.

Analysis of autophagosome formation using lentiviral biosensors for live fluorescent cellular imaging.

Long K, Mohan C, Anderl J, Huryn-Selvar K, Liu H, Su K, Santos M, Hsu M, Armstrong L, Ma J.

Methods Mol Biol. 2015;1219:157-69. doi: 10.1007/978-1-4939-1661-0_12.

PMID:
25308268
9.

Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).

Niewerth D, Jansen G, Riethoff LF, van Meerloo J, Kale AJ, Moore BS, Assaraf YG, Anderl JL, Zweegman S, Kaspers GJ, Cloos J.

Mol Pharmacol. 2014 Jul;86(1):12-9. doi: 10.1124/mol.114.092114. Epub 2014 Apr 15.

10.

A novel, non-radioactive eukaryotic in vitro transcription assay for sensitive quantification of RNA polymerase II activity.

Voss C, Schmitt B, Werner-Simon S, Lutz C, Simon W, Anderl J.

BMC Mol Biol. 2014 Apr 3;15:7. doi: 10.1186/1471-2199-15-7.

11.

Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.

Niewerth D, van Meerloo J, Jansen G, Assaraf YG, Hendrickx TC, Kirk CJ, Anderl JL, Zweegman S, Kaspers GJ, Cloos J.

Biochem Pharmacol. 2014 May 1;89(1):43-51. doi: 10.1016/j.bcp.2014.02.005. Epub 2014 Feb 16.

PMID:
24552657
12.

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.

Niewerth D, Kaspers GJ, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, Blank JL, van de Ven PM, Zweegman S, Jansen G, Cloos J.

J Hematol Oncol. 2014 Jan 13;7:7. doi: 10.1186/1756-8722-7-7.

13.

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.

Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J.

Haematologica. 2013 Dec;98(12):1896-904. doi: 10.3324/haematol.2013.092411. Epub 2013 Sep 20.

14.

Antibody-drug conjugate payloads.

Anderl J, Faulstich H, Hechler T, Kulke M.

Methods Mol Biol. 2013;1045:51-70. doi: 10.1007/978-1-62703-541-5_4. Review.

PMID:
23913141
15.

Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.

Gupta S, Wang L, Anderl J, Slifker MJ, Kirk C, Kruger WD.

Hum Mutat. 2013 Aug;34(8):1085-93. doi: 10.1002/humu.22335. Epub 2013 May 13.

16.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G.

Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2.

17.

Chemical modification allows phallotoxins and amatoxins to be used as tools in cell biology.

Anderl J, Echner H, Faulstich H.

Beilstein J Org Chem. 2012;8:2072-84. doi: 10.3762/bjoc.8.233. Epub 2012 Nov 27.

18.

Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.

Moldenhauer G, Salnikov AV, Lüttgau S, Herr I, Anderl J, Faulstich H.

J Natl Cancer Inst. 2012 Apr 18;104(8):622-34. doi: 10.1093/jnci/djs140. Epub 2012 Mar 27.

PMID:
22457476
19.

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ.

Clin Cancer Res. 2011 May 1;17(9):2734-43. doi: 10.1158/1078-0432.CCR-10-1950. Epub 2011 Mar 1.

20.

A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicity.

Anderl JL, Redpath S, Ball AJ.

J Vis Exp. 2009 May 5;(27). pii: 1173. doi: 10.3791/1173.

21.

Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R.

Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, Weller M, Wick W, Platten M.

Stem Cells. 2009 Apr;27(4):909-19. doi: 10.1002/stem.7.

22.

Retention and biodistribution of microspheres injected into ischemic myocardium.

Anderl JN, Robey TE, Stayton PS, Murry CE.

J Biomed Mater Res A. 2009 Mar 1;88(3):704-10. doi: 10.1002/jbm.a.31917.

PMID:
18335529
23.
24.

Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin.

Anderl JN, Franklin MJ, Stewart PS.

Antimicrob Agents Chemother. 2000 Jul;44(7):1818-24.

Supplemental Content

Loading ...
Support Center